Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | F9 | P00740 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792435 | 0.90 | MAOB (0.54) | MAOBMAOAACHEF9F10 | |
| SCHEMBL5090273 | 0.83 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL5382147 | 0.83 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL5087372 | 0.79 | MAOB (0.61) | MAOBMAOA | |
| SCHEMBL5096562 | 0.79 | MAOB (0.50) | MAOBACHENR4A1 | |
| SCHEMBL5089231 | 0.79 | MAOB (0.71) | MAOBMAOA | |
| SCHEMBL31451980 | 0.78 | MAOB (0.55) | MAOBMAOAACHEPPARA | |
| SCHEMBL7028448 | 0.77 | MAOB (0.67) | MAOBMAOAACHEPPARA | |
| SCHEMBL24749533 | 0.77 | GAA (0.53) | MAOBMAOAACHE | |
| Hydrochloric Acid SCHEMBL7024049 | 0.77 | CACNA1C (0.67) | MAOBMAOAACHEPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722929-B2 | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNJ2, KCNA2 | MAOB 808/4885MAOA 1086/4885ACHE 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.